SCHEMBL21541673

SCHEMBL21541673

CCOC(=O)CC1(O)CCN(C(=O)OC(C)(C)C)CC1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.36
ALDH1A1 P00352 4/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GLA P06280 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
USP2 O75604 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
ADORA1 P30542 1/20 0.34
JAK2 O60674 2/20 0.34
JAK1 P23458 2/20 0.34
GPR119 Q8TDV5 1/20 0.34
SETD7 Q8WTS6 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20354988 0.87 NR1H2 (0.36) NR1H2ALDH1A1MEN1KMT2AMAPT
SCHEMBL20486698 0.86 NR1H2 (0.35) NR1H2ALDH1A1MEN1KMT2AMAPT
SCHEMBL21541692 0.85 NR1H2 (0.40) NR1H2ALDH1A1MEN1KMT2AMAPT
SCHEMBL31401105 0.82 NR1H2 (0.43) NR1H2ALDH1A1MEN1KMT2AMAPT
SCHEMBL25684315 0.81 NR1H2 (0.40) NR1H2ALDH1A1MEN1KMT2AMAPT
SCHEMBL25164566 0.80 ALDH1A1 (0.33) NR1H2ALDH1A1MEN1KMT2AMAPT
SCHEMBL240646 0.79 SMN1; SMN2 (0.43) ALDH1A1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL3494375 0.78 SMN1; SMN2 (0.47) ALDH1A1MEN1KMT2AHPGDRECQL
SCHEMBL3314428 0.77 SMN1; SMN2 (0.41) ALDH1A1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL21551293 0.77 SMN1; SMN2 (0.43) ALDH1A1MEN1KMT2AHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3567030-B1 QUINAZOLINE COMPOUND FOR EGFR INHIBITION MEDSHINE DISCOVERY INC (CN) 2022-02-09 EP disclosed
US-11040984-B2 Quinazoline compound for EGFR inhibition MEDSHINE DISCOVERY INC. (CN) 2021-06-22 US disclosed
US-20200190107-A1 QUINAZOLINE COMPOUND FOR EGFR INHIBITION MEDSHINE DISCOVERY INC. (CN) 2020-06-18 US disclosed
EP-3567030-A1 QUINAZOLINE COMPOUND FOR EGFR INHIBITION Medshine Discovery Inc. (CN) 2019-11-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040984-B2 Quinazoline compound for EGFR inhibition EGFR, ERBB2, ERBB4 NR1H2 2047/4885ALDH1A1 3390/4885MEN1 3587/4885
US-20200190107-A1 QUINAZOLINE COMPOUND FOR EGFR INHIBITION EGFR, ERBB2, ERBB4 NR1H2 2047/4885ALDH1A1 3390/4885MEN1 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.